One Health Trust, formerly the Center for Disease Dynamics, Economics & Policy (CDDEP), is a public health research organization with headquarters in Washington, D.C., and Bangalore, India. 

In 2022, CDDEP announced its imminent transition to becoming the One Health Trust in order to expand the scope of the organization’s work to include topics such as climate change and planetary health.

Overview
One Health Trust's team of economists, epidemiologists, disease modelers, policy and risk analysts carry out research on malaria, tuberculosis, COVID-19, antimicrobial resistance, disease control priorities, environmental health, and various other topics.  Research is divided across eight areas: antimicrobial resistance; communicable disease dynamics; gender, equity, and livelihoods; food, climate & health; noncommunicable diseases; health and development;vaccines and immunization; and OxygenForIndia.

Two One Health Trust initiatives focus on antimicrobial resistance as a public health crisis. The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) consortium, which includes OHT, conducts data surveillance and analysis in Africa to determine the extent of AMR on the continent. The African Society for Laboratory Medicine released a summary of the project’s findings in September 2022. In addition, The Global Antibiotic Resistance Partnership is developing actionable policy proposals on antibiotic resistance for five low- and middle-income countries: China, India, Kenya, South Africa, and Vietnam.

Projects
The Global Antibiotic Resistance Partnership (GARP) was started in 2009 to create a platform for developing actionable policy proposals on antibiotic resistance in low-income and middle-income countries. During the first three years, Phase 1 of GARP established national working groups in four countries: India, Kenya, South Africa and Vietnam. GARP Phase 1 culminated in the 1st Global Forum on Bacterial Infections: Balancing Treatment Access and Antibiotic Resistance on October 3–5, 2011, in New Delhi, India. Since GARP Phase 2 began in 2012, national working groups have been established in Mozambique, Nepal, Tanzania and Uganda.

The Oxygen For India initiative was founded by the One Health Trust in April 2021 to alleviate the national shortage of medical oxygen in India during the COVID-19 pandemic. OxygenForIndia successfully delivered 20,000 reusable oxygen cylinders and 3,000 oxygen concentrators in 57 urban and rural centers in India, and is working with national partners Swasth Alliance to establish long-term stakeholder investment.

Notable work
The stated objective of the Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) consortium, funded by the Fleming Fund is to assess the burden of AMR in Africa by collecting and analyzing data in several African countries. The MAAP consortium comprises the African Society for Laboratory Medicine, OHT, IQVIA, Africa Centers for Disease Control and Prevention, West African Health Organization, the East Central & Southern Africa Health Community (ECSA-HC), and Innovative Support to Emergencies, Diseases, and Disasters (InSTEDD).
 
The MAAP project collected retrospective data on AMR and antimicrobial use (AMU) from public and private laboratories and pharmacies in 14 different African nations. The African Society for Laboratory Medicine released a summary of the project’s findings in September 2022.
 
ResistanceMap was created in 2010 with the stated objective to share antibiotic use and susceptibility data from the United States. It is a web-based platform for collecting and disseminating data on antibiotic use and resistance worldwide. ResistanceMap was the first initiative to provide access to resistance data from several LMICs, including India, South Africa, and Vietnam. These data demonstrated high and increasing rates of antibiotic resistance in LMICs. Currently, ResistanceMap displays resistance data from 46 countries.
 
One component of ResistanceMap is the Drug Resistance Index (DRI), which is a composite measure that combines the ability of antibiotics to treat infections with the extent of their use in clinical practice. The DRI provides an aggregate trend measure of the efficacy of available drugs, and was compared by Science Magazine to a Dow Jones for drug resistance.
 
After introducing the DRI in a paper in BMJ Open in 2011, One Health Trust began to provide technical support to hospitals in India, Nepal, and Kenya to track DRIs in their local settings and measure the potential impact of their antimicrobial stewardship interventions and infection control practices. The documented goal of the initiative is to calculate DRIs for all nations. The project's early findings were presented at the 17th International Conference on Infectious Diseases and reported in the International Journal of Infectious Diseases.

References

External links
 Extending the Cure (ETC) 
 Global Antibiotic Resistance Partnership (GARP)

Medical research institutes in Washington, D.C.
Organizations established in 2009